SK Biopharmaceuticals said it aims to grow into one of the top 10 global healthcare companies by 2030 in its online presentation on Friday.

The company will focus on expanding its portfolios in the U.S., developing different regional business models, finding additional areas for creating new pipelines, and focusing on research and development (R&D) using the latest technology.

SK Biopharmaceuticals plans to strengthen its leadership in neurological diseases by launching new medications and discovering new promising drug candidates to secure global competitiveness, according to the company’s “Financial Story.” It also will develop and implement various business models through strategic partnerships in Europe and Asia.

For the novel drug R&D, the company aims to add more pipelines developing candidates for brain diseases, including epilepsy, rare neurological disorders, mental illness, and cancers, on top of the existing portfolio for central nervous system disease.

SK Biopharmaceuticals CEO Cho Jeong-woo said the company would accelerate the discovery of new drug candidates by combining the latest ribonucleic acid (RNA) technology and artificial intelligence (AI) and digital transformation (DT).

The company also published its first sustainability report to launch environmental, social, and governance management.

The report includes the company's long-term projects for creating healthcare value, making sustainable partnerships, fostering competent members, performing transparent and ethical management, and minimizing the influence on the environment, in addition to the company's goal to become carbon neutral by 2040.

"SK Biopharmaceuticals will fulfill the pivotal role of SK Group's biopharmaceutical businesses as we have presented our visions through the Financial Story and ESG (environmental, social, and governance) report," Cho said. "We will become one of the top tier drug developers with a corporate value of 50 trillion won ($44 billion)  by expanding portfolios."